2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HK$
arrow_downward
-0,90%(-0,44) 1 d.
16. okt., 16:08:14 GMT+8 · HKD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 2269…
Atvērt
49,98 HK$
Augsta
50,85 HK$
Zema
45,82 HK$
Tirgus kapitalizācija
198,43 mljrd.
Vid. apjoms
30,42 milj.
Apjoms
55,18 milj.
Cenas/peļņas attiecība
34,48
Augstākā 52 ned.
58,00 HK$
Zemākā 52 ned.
28,48 HK$
Peļņa uz vienu akciju
1,40 HK$
Apgrozībā esošās akcijas
1,23 mljrd.
Darbinieku skaits
15 tūkst.
Atvērt
49,98 HK$
Augsta
50,85 HK$
Zema
45,82 HK$
Tirgus kapitalizācija
198,43 mljrd.
Vid. apjoms
30,42 milj.
Apjoms
55,18 milj.
Cenas/peļņas attiecība
34,48
Augstākā 52 ned.
58,00 HK$
Zemākā 52 ned.
28,48 HK$
Peļņa uz vienu akciju
1,40 HK$
Apgrozībā esošās akcijas
1,23 mljrd.
Darbinieku skaits
15 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Simply Wall Street
·
pirms 14 minūtēm
Did FDA Filings Just Shift Cogent Biosciences Stock Investment Narrative?
Yahoo Finance
·
pirms 4 stundām
Michael Burry Warns Stock Market Could Be Months Away From A 2000-Style Reckoning — ‘The Preconditions Seem Set For Fireworks’
The Motley Fool
·
pirms 58 minūtēm
Should You Invest in the S&P 500 Right Now or Wait? There's 1 Clear Answer
AOL.com
·
pirms 4 stundām
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Profils
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Par “WuXi Biologics (Cayman) Inc”
ĢenerāldirektorsZhisheng Chen
Darbinieki14,7 tūkst.
Dibināšanas datums2010
Galvenais birojs-
Sektors-
Tīmekļa vietnewuxibiologics.com